# Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

> **NCT02059135** · PHASE3 · COMPLETED · sponsor: **rEVO Biologics** · enrollment: 120 (actual)

## Conditions studied

- Preeclampsia

## Interventions

- **BIOLOGICAL:** Recombinant human antithrombin (ATryn)
- **OTHER:** Normal Saline 0.9%

## Key facts

- **NCT ID:** NCT02059135
- **Lead sponsor:** rEVO Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-11
- **Primary completion:** 2016-05-18
- **Final completion:** 2016-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059135, "Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02059135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*